Metabolism of Amitriptyline in Patients with Chronic Renal Failure

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1984 Jan 1

PMID 6723762

Citations 6

Authors

M SANDOZ

S VANDEL

B Vandel

B Bonin

B Hory

Y St Hillier

R VOLMAT

Affiliations

Soon will be listed here.

Abstract

The metabolism of amitriptyline (AMT) has been studied in two groups of depressed in-patients on long term AMT therapy: 11 patients with no other major disease and 8 patients with chronic renal failure, who were being dialysed. The patients with renal insufficiency had decreased concentrations of AMT, nortriptyline (NT) and their unconjugated hydroxymetabolites compared to patients with normal kidney function. The plasma levels of conjugated products were extremely high in the uraemics. The latter metabolites are probably inert. The reduced concentration of unconjugated hydroxymetabolites , which are active compounds, may decrease the clinical effectiveness of the drug.

Citing Articles

Pain management in patients with chronic kidney disease and end-stage kidney disease.

Roy P, Weltman M, Dember L, Liebschutz J, Jhamb M Curr Opin Nephrol Hypertens. 2020; 29(6):671-680.

PMID: 32941189 PMC: 7753951. DOI: 10.1097/MNH.0000000000000646.

Neuropsychiatric manifestation after a stroke: newly developed symptoms or side-effect of drug?.

Tan E, Aziz N, Ahmad S BMJ Case Rep. 2012; 2012.

PMID: 22907854 PMC: 4544885. DOI: 10.1136/bcr-2012-006518.

Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Crone C, Gabriel G Clin Pharmacokinet. 2004; 43(6):361-94.

PMID: 15086275 DOI: 10.2165/00003088-200443060-00002.

Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Furlanut M, Benetello P, Spina E Clin Pharmacokinet. 1993; 24(4):301-18.

PMID: 8491058 DOI: 10.2165/00003088-199324040-00004.

Guide to drug dosage in renal failure.

Bennett W Clin Pharmacokinet. 1988; 15(5):326-54.

PMID: 3060292 DOI: 10.2165/00003088-198815050-00005.

References

Biggs S, Chasseaud L, Hawkins D, Midgley I . Determination of amitriptyline and its major basic metabolites in human urine by high-performance liquid chromatography. Drug Metab Dispos. 1979; 7(4):233-6. View

Odar-Cederlof I, Borga O . Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding. Eur J Clin Pharmacol. 1974; 7(1):31-7. DOI: 10.1007/BF00614387. View

Kampf D, Roots I, Hildebrandt A . Urinary excretion of D-glucaric acid, an indicator of drug metabolizing enzyme activity, in patients with impaired renal function. Eur J Clin Pharmacol. 1980; 18(3):255-61. DOI: 10.1007/BF00563008. View

McCormick M, Navarro V . Prevalence of chronic renal failure and access to dialysis. Int J Epidemiol. 1973; 2(3):247-55. DOI: 10.1093/ije/2.3.247. View

Tillement J, Lhoste F, Giudicelli J . Diseases and drug protein binding. Clin Pharmacokinet. 1978; 3(2):144-54. DOI: 10.2165/00003088-197803020-00004. View

Yousef I, Tuchweber B, Vonk R, Masse D, Audet M, Roy C . Lithocholate cholestasis--sulfated glycolithocholate-induced intrahepatic cholestasis in rats. Gastroenterology. 1981; 80(2):233-41. View

VANDEL S, Vandel B, SANDOZ M, ALLERS G, Bechtel P, VOLMAT R . Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline. Eur J Clin Pharmacol. 1978; 14(3):185-90. DOI: 10.1007/BF02089958. View

Gram L, OVERO K, Kirk L . Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man. Am J Psychiatry. 1974; 131(8):863-6. DOI: 10.1176/ajp.131.8.863. View

Potter W, Calil H, Manian A, Zavadil A, Goodwin F . Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity. Biol Psychiatry. 1979; 14(4):601-13. View

10.

Reidenberg M, Odar-Cederlof I, von Bahr C, Borga O, Sjoqvist F . Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med. 1971; 285(5):264-7. DOI: 10.1056/NEJM197107292850506. View

11.

Verbeeck R, Branch R, Wilkinson G . Drug metabolites in renal failure: pharmacokinetic and clinical implications. Clin Pharmacokinet. 1981; 6(5):329-45. DOI: 10.2165/00003088-198106050-00001. View

12.

Gugler R, Kurten J, Jensen C, Klehr U, Hartlapp J . Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol. 1979; 15(5):341-7. DOI: 10.1007/BF00558438. View

13.

Odar-Cederlof I, Vessman J, Alvan G, Sjoqvist F . Oxazepam disposition in uremic patients. Acta Pharmacol Toxicol (Copenh). 1977; 40 Suppl 1(1):52-62. View

14.

Meyers M, Slikker W, Pascoe G, Vore M . Characterization of cholestasis induced by estradiol-17 beta-D-glucuronide in the rat. J Pharmacol Exp Ther. 1980; 214(1):87-93. View

15.

Vandel B, SANDOZ M, VANDEL S, ALLERS G, VOLMAT R . Biotransformation of amitriptyline in depressive patients: urinary excretion of seven metabolites. Eur J Clin Pharmacol. 1982; 22(3):239-45. DOI: 10.1007/BF00545222. View

16.

Mellstrom B, Bertilsson L, Sawe J, Schulz H, Sjoqvist F . E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther. 1981; 30(2):189-93. DOI: 10.1038/clpt.1981.147. View

17.

Bertilsson L, Eichelbaum M, Mellstrom B, Sawe J, Schulz H, Sjoqvist F . Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci. 1980; 27(18):1673-7. DOI: 10.1016/0024-3205(80)90642-6. View

18.

Dawling S, Lynn K, Rosser R, Braithwaite R . Nortriptyline metabolism in chronic renal failure: metabolite elimination. Clin Pharmacol Ther. 1982; 32(3):322-9. DOI: 10.1038/clpt.1982.167. View

19.

Lowenthal D, Oie S, Van Stone J, Briggs W, Levy G . Pharmacokinetics of acetaminophen elimination by anephric patients. J Pharmacol Exp Ther. 1976; 196(3):570-8. View

20.

DeBaun J, Miller E, Miller J . N-hydroxy-2-acetylaminofluorene sulfotransferase: its probable role in carcinogenesis and in protein-(methion-S-yl) binding in rat liver. Cancer Res. 1970; 30(3):577-95. View